JP2007514752A5 - - Google Patents

Download PDF

Info

Publication number
JP2007514752A5
JP2007514752A5 JP2006545462A JP2006545462A JP2007514752A5 JP 2007514752 A5 JP2007514752 A5 JP 2007514752A5 JP 2006545462 A JP2006545462 A JP 2006545462A JP 2006545462 A JP2006545462 A JP 2006545462A JP 2007514752 A5 JP2007514752 A5 JP 2007514752A5
Authority
JP
Japan
Prior art keywords
aib
acc
phe
ala
2nal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2006545462A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007514752A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/042389 external-priority patent/WO2005058252A2/en
Publication of JP2007514752A publication Critical patent/JP2007514752A/ja
Publication of JP2007514752A5 publication Critical patent/JP2007514752A5/ja
Ceased legal-status Critical Current

Links

JP2006545462A 2003-12-16 2004-12-16 Ｇｌｐ−１医薬組成物 Ceased JP2007514752A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52993203P 2003-12-16 2003-12-16
PCT/US2004/042389 WO2005058252A2 (en) 2003-12-16 2004-12-16 Glp-1 pharmaceutical compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010224218A Division JP2011001381A (ja) 2003-12-16 2010-10-01 Ｇｌｐ−１医薬組成物

Publications (2)

Publication Number Publication Date
JP2007514752A JP2007514752A (ja) 2007-06-07
JP2007514752A5 true JP2007514752A5 (https=) 2010-05-13

Family

ID=34700069

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006545462A Ceased JP2007514752A (ja) 2003-12-16 2004-12-16 Ｇｌｐ−１医薬組成物
JP2010224218A Pending JP2011001381A (ja) 2003-12-16 2010-10-01 Ｇｌｐ−１医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010224218A Pending JP2011001381A (ja) 2003-12-16 2010-10-01 Ｇｌｐ−１医薬組成物

Country Status (7)

Country Link
US (1) US7521527B2 (https=)
EP (1) EP1694278A4 (https=)
JP (2) JP2007514752A (https=)
AR (1) AR047776A1 (https=)
CA (1) CA2550695A1 (https=)
TW (1) TWI353250B (https=)
WO (1) WO2005058252A2 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7635463B2 (en) 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
WO2003072143A1 (en) * 2002-02-27 2003-09-04 Pharmain, Ltd. Compositions for delivery of therapeutics and other materials, and methods of making and using the same
WO2005112977A2 (en) * 2004-04-23 2005-12-01 Pharmain, Ltd. Compositions for treatment with glucagon-like peptide, and methods of making and using the same
MX2008001468A (es) * 2005-06-30 2008-04-07 Sod Conseils Rech Applic Composiciones farmaceuticas del peptido similar al glucagon-1.
ES2736184T3 (es) 2005-08-19 2019-12-26 Amylin Pharmaceuticals Llc Exendina para el tratamiento de la diabetes y la reducción del peso corporal
KR101529318B1 (ko) 2005-12-19 2015-06-16 파마인 코포레이션 치료제를 전달하기 위한 소수성 코어 담체 조성물, 이조성물의 제조 방법 및 그 조성물의 이용 방법
CA2674209A1 (en) * 2006-12-29 2008-07-10 Ipsen Pharma S.A.S. Glp-1 pharmaceutical compositions
WO2008082656A1 (en) * 2006-12-29 2008-07-10 Ipsen Pharma S.A.S. Glp-1 pharmaceutical compositions
US7960336B2 (en) * 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US8563527B2 (en) * 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
US20100256056A1 (en) * 2007-09-07 2010-10-07 Zheng Xin Dong Analogues of exendin-4 and exendin-3
US20090176892A1 (en) * 2008-01-09 2009-07-09 Pharmain Corporation Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
WO2009139855A2 (en) * 2008-05-14 2009-11-19 Ipsen Pharma S.A.S. Pharmaceutical compositions of somatostatin-dopamine conjugates
EP2303313B1 (en) 2008-05-21 2015-10-28 Amylin Pharmaceuticals, LLC Exendins to lower cholestrol and triglycerides
WO2010016936A1 (en) * 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Pharmaceutical compositions of analogues of glucose-dependent insulinotropic polypeptide
US9314509B2 (en) 2009-11-16 2016-04-19 Ipsen Pharma S.A.S. Pharmaceutical compositions of melanocortin receptor ligands
MX343499B (es) * 2010-03-15 2016-11-08 Ipsen Pharma Sas Composiciones farmaceuticas de ligandos receptores de secretagoga de la hormona de crecimiento.
EP2384733B1 (de) 2010-05-07 2016-07-27 Ivoclar Vivadent AG Antimikrobielle Dentalwerkstoffe
TWI523863B (zh) 2012-11-01 2016-03-01 艾普森藥品公司 體抑素－多巴胺嵌合體類似物
CN104768565B (zh) 2012-11-01 2017-04-26 益普生制药股份有限公司 促生长素抑制素类似物及其二聚体
HRP20240485T1 (hr) 2017-08-24 2024-07-05 Novo Nordisk A/S Pripravci glp-1 i njihova upotreba
PE20230819A1 (es) 2020-02-18 2023-05-19 Novo Nordisk As Composiciones y usos de glp-1

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783441A (en) * 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
ATE110083T1 (de) 1986-05-05 1994-09-15 Gen Hospital Corp Insulinotropes hormon.
ATE164852T1 (de) 1990-01-24 1998-04-15 Douglas I Buckley Glp-1-analoga verwendbar in der diabetesbehandlung
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US6221958B1 (en) * 1993-01-06 2001-04-24 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
NZ250844A (en) 1993-04-07 1996-03-26 Pfizer Treatment of non-insulin dependant diabetes with peptides; composition
US6284727B1 (en) * 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
EP0658568A1 (en) 1993-12-09 1995-06-21 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5574008A (en) 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
US5595760A (en) * 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5512549A (en) * 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US20010006943A1 (en) * 1994-12-23 2001-07-05 Ejvind Jensen Protracted GLP-1 compositions
US5980945A (en) * 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
WO1997029180A1 (en) 1996-02-06 1997-08-14 Eli Lilly And Company Diabetes therapy
US6264970B1 (en) * 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
DE19629640C1 (de) 1996-07-23 1997-08-28 Metallgesellschaft Ag Verfahren zur Herstellung von kristallinem D-Sorbit
US6458924B2 (en) * 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
US5981488A (en) 1997-03-31 1999-11-09 Eli Lillly And Company Glucagon-like peptide-1 analogs
US6663899B2 (en) * 1997-06-13 2003-12-16 Genentech, Inc. Controlled release microencapsulated NGF formulation
US6380357B2 (en) 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
EP1061946B1 (en) 1998-02-27 2004-04-28 Novo Nordisk A/S Glp-1 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
AU2610599A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
EP1061948B1 (en) * 1998-03-20 2003-01-02 Takeda Chemical Industries, Ltd. Sustained-release preparation of physiologically active polypeptide and production thereof
FR2776520B1 (fr) * 1998-03-25 2000-05-05 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
FR2777283B1 (fr) 1998-04-10 2000-11-24 Adir Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent
RU2205188C2 (ru) * 1998-06-30 2003-05-27 Ново Нордиск А/С Затравочные кристаллы для получения пептидов или протеинов
US6720407B1 (en) * 1998-08-28 2004-04-13 Eli Lilly And Company Method for administering insulinotropic peptides
JP2002538081A (ja) * 1998-12-07 2002-11-12 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス Ｇｌｐ−１の類似体
DE69922043T2 (de) * 1998-12-07 2005-11-24 Société de Conseils de Recherches et d'Applications Scientifiques S.A.S. Glp-1 analoge
NZ512663A (en) * 1999-01-14 2004-05-28 Amylin Pharmaceuticals Inc Novel exendin agonist formulations and methods of administration thereof
WO2001000223A2 (en) 1999-06-25 2001-01-04 Minimed Inc. Multiple agent diabetes therapy
US6541225B1 (en) * 2000-01-26 2003-04-01 Raven Biotechnologies, Inc. Methods and compositions for generating human monoclonal antibodies
AU2001228327A1 (en) 2000-01-31 2001-08-14 Novo-Nordisk A/S Crystallisation of a glp-1 analogue
US6844321B2 (en) * 2000-01-31 2005-01-18 Novo Nordisk A/S Crystallization of a GLP-1 analogue
ATE424413T1 (de) * 2000-06-16 2009-03-15 Lilly Co Eli Analoge des glucagon-ähnlichen peptids-1
US7144863B2 (en) * 2001-06-01 2006-12-05 Eli Lilly And Company GLP-1 formulations with protracted time action
AU2002316811A1 (en) * 2001-06-28 2003-03-03 Novo Nordisk A/S Stable formulation of modified glp-1
CA2463908A1 (en) * 2001-10-18 2003-04-24 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
WO2003035099A1 (en) 2001-10-19 2003-05-01 Eli Lilly And Company Biphasic mixtures of glp-1 and insulin

Similar Documents

Publication Publication Date Title
JP2007514752A5 (https=)
RU2485135C2 (ru) Соединения оксинтомодулина (варианты), фармацевтическая композиция на их основе, способы лечения и профилактики ожирения и сопутствующих заболеваний (варианты) и лекарственное средство (варианты)
CN1247260C (zh) 甲状旁腺素类似物
JP3787242B2 (ja) グルカゴン様ペプチド−１（７−３７）の類似体である新規ペプチド化合物、それらの製造法、およびそれらを含有する製剤組成物
US4410512A (en) Combinations having synergistic pituitary growth hormone releasing activity
CN1137898C (zh) 甲状旁腺素的类似物
Plucinska et al. Multiple binding modes for the receptor-bound conformations of cyclic AII agonists
JP2013543497A5 (https=)
AU2010216372B2 (en) Cytotoxic conjugates having neuropeptide Y receptor binding compound
EP2019118B1 (en) Method for synthesizing thymosins
MXPA03001721A (es) Peptidos ciclicos selectivos.
JP2009537624A5 (https=)
NZ599161A (en) Method for activation of helper t cell and composition for use in the method
JPH05163298A (ja) 新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤
LU87495A1 (fr) Nouveaux derives peptidiques,leur preparation et leur utilisation omme medicaments
HUP0104579A2 (hu) GLP-1 analógok, ezeket tartalmazó gyógyászati készítmények, valamint a vegyületek alkalmazása
US4410513A (en) Synthetic peptides having pituitary growth hormone releasing activity
JP2013500990A5 (https=)
CA2040264A1 (en) Parathyroid hormone antagonists
JPH06504795A (ja) 新規アミリン拮抗剤ペプチドおよびその使用
KR100236413B1 (ko) Grf(쥐이알에프) 유사체 xi
JPS58116443A (ja) 新規ペプチドおよびその製法
JPH01313499A (ja) チロシンサルフエートまたはチロシンホスフエートの残基を含有するペプチドの類似体
PT94553A (pt) Processo para a preparacao de novos analogos ii de peptidos intestinais vasoactivos (vip) e de composicoes farmaceuticas que os contem
JP6231882B2 (ja) 放射性コンジュゲーション方法